Cel-Sci (NYSEAMERICAN:CVM) Shares Down 0.9% – What’s Next?

Cel-Sci Corporation (NYSEAMERICAN:CVM) was down 0.9% on Thursday . The stock traded as low as $3.27 and last traded at $3.31. Approximately 30,767 shares changed hands during mid-day trading, a decline of 51% from the average daily volume of 62,532 shares. The stock had previously closed at $3.34.

Cel-Sci Stock Down 0.9%

The firm has a market cap of $28.10 million, a P/E ratio of -0.34 and a beta of 0.99. The company has a quick ratio of 1.35, a current ratio of 1.39 and a debt-to-equity ratio of 0.45. The firm has a fifty day moving average of $3.97 and a 200-day moving average of $5.69.

Cel-Sci (NYSEAMERICAN:CVM) last issued its quarterly earnings results on Tuesday, December 23rd. The company reported ($0.76) EPS for the quarter.

Hedge Funds Weigh In On Cel-Sci

Several hedge funds and other institutional investors have recently made changes to their positions in the company. HighTower Advisors LLC bought a new stake in Cel-Sci during the fourth quarter worth $53,000. HRT Financial LP bought a new position in shares of Cel-Sci in the 4th quarter valued at about $60,000. XTX Topco Ltd bought a new position in shares of Cel-Sci in the 4th quarter valued at about $66,000. US Bancorp DE acquired a new position in shares of Cel-Sci during the 3rd quarter worth about $80,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Cel-Sci during the 4th quarter worth about $81,000. 12.08% of the stock is owned by institutional investors.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.